All Cases

The petition demonstrated extraordinary ability through 11 peer-reviewed articles, a high citation count of 766 from 58 countries, and significant judging experience with 37 peer reviews. The work's impact on public health and national safety priorities was a key factor.

The petition was approved based on a record of 21 peer-reviewed journal articles and 3 patents reflecting commercially relevant innovations. The petitioner demonstrated significant global influence through 1,189 citations and established professional standing by completing 128 peer reviews for scientific journals. These metrics satisfied the EB-1A criteria for scholarly articles, original contributions, and judging.

The petition was approved based on the petitioner's authorship of 27 peer-reviewed articles and 17 abstracts, which garnered 485 citations from researchers in over 40 countries. His work ranked in the top 10% of most-cited publications in pharmacology for several years. Additionally, he completed over 60 peer reviews and received research grants from the NIH and the National Research Foundation of South Korea.

The petition was approved based on a strong scholarly record including 14 journal articles and 1,966 citations, placing the applicant in the top 1% of the field. Additional evidence included 21 peer-review assignments for high-impact journals and a first-authored patent, satisfying the EB-1A criteria for scholarly articles, judging, and original contributions.

The petition was approved based on 27 peer-reviewed journal articles and 567 citations, placing the petitioner in the top 1% of researchers in his field. Additionally, he completed 61 peer reviews for top-tier journals and served on editorial boards, satisfying the EB-1A criteria for scholarly articles, judging, and original contributions.

The approval was based on a significant publication record of 28 journal articles and a citation count exceeding 360, placing the petitioner in the top 1% of his field. Additionally, his 25 peer reviews and original contributions to antimicrobial and antidiabetic agents satisfied the EB-1A criteria.

The petition was approved based on the satisfaction of at least three EB-1A criteria: authorship of scholarly articles, participation as a judge of the work of others, and original scientific contributions of major significance. Specific metrics included 8 peer-reviewed publications in elite journals like Nature Microbiology, 260 citations placing him in the top 1% of his field, and the completion of over 20 peer reviews for high-impact journals.

The petition was approved based on the authorship of 52 peer-reviewed journal articles and a massive citation count of 7,116, placing the petitioner in the top 1% of the field. Additionally, the petitioner demonstrated significant peer recognition through over 200 journal reviews and editorial board service. The evidence satisfied the EB-1A criteria for scholarly articles, original contributions, and judging the work of others.

The petition was approved based on meeting at least three EB-1A criteria: authorship of 16 peer-reviewed articles, 301 citations demonstrating international influence, and a significant record of 50 peer reviews for high-impact journals. Additionally, the petitioner's work on the sustainable synthesis of amidoalkyl naphthols was recognized as an original contribution of major significance to the pharmaceutical industry.

The petition was approved based on meeting at least three EB-1A criteria: authorship of scholarly articles, participation as a judge of others' work, and original scientific contributions of major significance. Specific metrics included 34 journal articles in high-impact venues like Cell Chemical Biology, 1,306 citations with an h-index of 17, and over 25 completed manuscript reviews. Evidence of the commercialization of key compounds further demonstrated the petitioner's extraordinary ability.